These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23767443)

  • 21. Governing through problems: the formulation of policy on amphetamine-type stimulants (ATS) in Australia.
    Fraser S; Moore D
    Int J Drug Policy; 2011 Nov; 22(6):498-506. PubMed ID: 22054738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [ACUTE POISONING WITH PSYCHOMIMETICS].
    BASTECKY J
    Act Nerv Super (Praha); 1964; 6():166-7. PubMed ID: 14164146
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pharmacological cognitive enhancement from a perspective of misuse and addiction].
    Franke AG; Soyka M
    Fortschr Neurol Psychiatr; 2015 Feb; 83(2):83-90. PubMed ID: 25723772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ACTIONS OF ASARONE ON BEHAVIOR, STRESS, AND HYPERPYREXIA, AND ITS INTERACTION WITH CENTRAL STIMULANTS.
    DANDIYA PC; MENON MK
    J Pharmacol Exp Ther; 1964 Jul; 145():42-6. PubMed ID: 14209509
    [No Abstract]   [Full Text] [Related]  

  • 25. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots.
    Poulin C
    Addiction; 2007 May; 102(5):740-51. PubMed ID: 17506151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of the abuse potential of modafinil using methylphenidate as a reference.
    Jasinski DR
    J Psychopharmacol; 2000 Mar; 14(1):53-60. PubMed ID: 10757254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
    Teuns GB; Geys HM; Geuens SM; Stinissen P; Meert TF
    J Pharmacol Toxicol Methods; 2014; 70(3):295-309. PubMed ID: 24632211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents.
    Williams RJ; Goodale LA; Shay-Fiddler MA; Gloster SP; Chang SY
    Am J Addict; 2004; 13(4):381-9. PubMed ID: 15370936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulant drug effects on touchscreen automated paired-associates learning (PAL) in rats.
    Roschlau C; Votteler A; Hauber W
    Learn Mem; 2016 Aug; 23(8):422-6. PubMed ID: 27421894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [DRUG TREATMENT OF MENTALLY DEFECTIVE CHILDREN].
    BRAUNER F; PRINGUET G
    Rev Neuropsychiatr Infant; 1963; 11():571-82. PubMed ID: 14200156
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications.
    Jain R; Stark JG
    Postgrad Med; 2016 Sep; 128(7):672-81. PubMed ID: 27467139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. INFLUENCE OF DOXAPRAM HYDROCHLORIDE ON RECOVERY FROM THIOPENTAL ANAESTHESIA.
    EVERS W; MALIK K; DOBKIN AB
    Can Anaesth Soc J; 1965 May; 12():281-7. PubMed ID: 14294789
    [No Abstract]   [Full Text] [Related]  

  • 33. Inconsistencies in the assumptions linking punitive sanctions and use of cannabis and new psychoactive substances in Europe.
    Hughes B; Matias J; Griffiths P
    Addiction; 2018 Dec; 113(12):2155-2157. PubMed ID: 29953686
    [No Abstract]   [Full Text] [Related]  

  • 34. Sensitization and cross-sensitization after chronic treatment with methylphenidate in adolescent Wistar rats.
    Valvassori SS; Frey BN; Martins MR; Réus GZ; Schimidtz F; Inácio CG; Kapczinski F; Quevedo J
    Behav Pharmacol; 2007 May; 18(3):205-12. PubMed ID: 17426484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Central nervous system stimulants and their potential risk of abuse in hyperkinetic disorders].
    Aanonsen NO
    Tidsskr Nor Laegeforen; 1999 Nov; 119(27):4040-2. PubMed ID: 10613094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines.
    National Toxicology Program
    NTP CERHR MON; 2005 Jul; (16):vii-III1. PubMed ID: 16130031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing abuse liability during drug development: changing standards and expectations.
    Schoedel KA; Sellers EM
    Clin Pharmacol Ther; 2008 Apr; 83(4):622-6. PubMed ID: 18212799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Ritalin ad blitz makes parents jumpy.
    Novak V
    Time; 2001 Sep; 158(10):62-3. PubMed ID: 11558351
    [No Abstract]   [Full Text] [Related]  

  • 39. Use of cognitive enhancers: methylphenidate and analogs.
    Carlier J; Giorgetti R; Varì MR; Pirani F; Ricci G; Busardò FP
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):3-15. PubMed ID: 30657540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans.
    Stoops WW; Glaser PE; Fillmore MT; Rush CR
    J Psychopharmacol; 2004 Dec; 18(4):534-43. PubMed ID: 15582920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.